The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

Overview of attention for article published in Frontiers in immunology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 8 news outlets

twitter: 14 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 12 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 15 X posts from 14 X users, with an upper bound of 54,692 followers.

🗑️ Will 'deep sixing' CD40 work?: A hexavalent CD40 agonist https://t.co/EJX3WwHo9d https://t.co/4GgYKL9KeZ

26 Jun 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-t…

25 Jun 2023

Reply Repost Favourite

RT @ProstateUKProfs: 📢 Exciting study showing anti-tumour effects of the CD40 agonist, HERA-CD40L, both alone and in combination with #radi…

25 Jun 2023

Reply Repost Favourite

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy https://t.co/DwaT2Ibbpm

13 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 11 additional X posts.